Get the latest news, insights, and market updates on ILMN (Illumina, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
3 Reasons to Sell ILMN and 1 Stock to Buy Instead
Illumina has been on fire lately. In the past six months alone, the company’s stock price has rocketed 47%, reaching $121.93 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation. Nov 19, 2025 - $ILMN
3 Unpopular Stocks with Warning Signs
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory. Nov 17, 2025 - $ILMN
Why The Narrative Around Illumina Is Shifting After Recent Analyst Upgrades and Sector Changes
Illumina's stock has seen a modest increase in its Fair Value Estimate, rising from $113.58 to $117.74. This reflects improved analyst confidence in the company's future prospects. This change comes amid stronger than expected quarterly results and expanding opportunities, but also ongoing uncertainties in global demand and sector outlook. Stay tuned to learn how you can keep ahead of Illumina’s evolving market narrative as new developments arise. Stay updated as the Fair Value for Illumina... Nov 16, 2025 - $ILMN
1 Momentum Stock with Promising Prospects and 2 We Avoid
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase. Nov 14, 2025 - $ILMN
Illumina whole-genome sequencing provides greater insight into genetic signals behind common diseases--according to Nature study
A study published today in Nature, authored by Illumina, Inc. (NASDAQ: ILMN) scientists and by collaborators from The University of Queensland demonstrates the importance of whole-genome sequencing (WGS) to more fully capture the genetics underlying complex human traits and diseases. Across all 34 diseases and traits studied, WGS captured nearly 90% of the genetic signal, based on heritability estimates from family studies. This marks a step toward solving the "missing heritability" problem, res Nov 12, 2025 - $ILMN
Illumina (ILMN): Exploring Valuation Following Recent Share Price Rebound
Illumina (ILMN) shares have shown steady movement recently, catching the attention of investors looking at biotech trends. With its latest quarterly performance, investors are considering how ongoing revenue and net income growth might influence the company’s valuation in the coming months. See our latest analysis for Illumina. Illumina’s share price has rebounded impressively over the last month with a 29.7% gain, helping to erase some of its earlier losses. However, the total shareholder... Nov 11, 2025 - $ILMN
Iambic Raises Over $100 Million in an Oversubscribed Round to Advance Its Portfolio of AI-Discovered Therapeutics and Leading Platform Technologies
SAN DIEGO, November 10, 2025--Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced raising over $100 million in an oversubscribed financing round with balanced support from new and existing investors, including Abingworth, Alexandria Venture Investments, Alumni Ventures, ARK, Ascenta, Catalio, Everbright Biofund, Freeflow Ventures, Illumina Ventures, Mubadala, Pegasus Tech Ventures, Qatar I Nov 10, 2025 - $ILMN
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple